Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DML54EA)

• Drug Name: Isopropyl dodecylfluorophosphonate Drug Info
• Synonyms: IDFP; Isopropyl dodecylfluorophosphonate; 615250-02-7; CHEMBL333149; Isopropyl Dodecylphosphonofluoridate; isopropyl dodecylphosphonofluoridoate; C15H32FO2P; SCHEMBL6115190; CTK8E7841; DTXSID00647212; MolPort-006-822-693; HMS3648I13; BDBM50132717; 1797AH; Propan-2-yl dodecylphosphonofluoridate; RT-013317; LS-192335; Dodecyl(fluoro)phosphinic acid isopropyl ester; SR-01000946223

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 24762154
  CAS Number: CAS 615250-02-7
  TTD Drug ID: DML54EA

Molecule-Related Drug Atlas

Drug(s) Targeting Fatty acid amide hydrolase (FAAH)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Propofol	DMB4OLE	Anaesthesia	9A78.6	Approved	[2]
Thiopental	DMGP8AX	Anaesthesia	9A78.6	Approved	[3]
JNJ-42165279	DM72GZO	Anxiety disorder	6B00-6B0Z	Phase 2	[4]
SSR411298	DMGTB2Q	Major depressive disorder	6A70.3	Phase 2	[5]
IW-6118	DMP42W1	Inflammation	1A00-CA43.1	Phase 2	[6]
PF-04457845	DMPRYU1	Liver disease	DB90-BD99	Phase 2	[7]
IPI-940	DMEIM5G	Pain	MG30-MG3Z	Phase 1	[8]
PMID29053063-Compound-11d	DMDRK68	N. A.	N. A.	Patented	[9]
Piperazine carbamic compound 1	DMZSYU4	N. A.	N. A.	Patented	[9]
Piperazine carbamic compound 2	DMMQ0ZO	N. A.	N. A.	Patented	[9]

Drug(s) Targeting Acetylcholinesterase (AChE)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tacrine	DM51FY6	Alzheimer disease	8A20	Approved	[10]
Donepezil	DMIYG7Z	Advanced cancer	2A00-2F9Z	Approved	[11]
Malathion	DMXZ84M	Pediculus capitis infestation	1G00.0	Approved	[12]
Galantamine	DMEO794	Alzheimer disease	8A20	Approved	[13]
Huperzine A	DMMAWLU	Alzheimer disease	8A20	Approved	[14]
Neostigmine	DM6T2J3	Myasthenia gravis	8C6Y	Approved	[15]
YM443	DMNZCI1	Functional dyspepsia	DD90.3	Approved	[16]
Ambenonium	DMOP0BL	Myasthenia gravis	8C6Y	Approved	[17]
Demecarium bromide	DMAYEU1	Open-angle glaucoma	9C61	Approved	[18]
Isoflurophate	DMBSK7X	Glaucoma/ocular hypertension	9C61	Approved	[19]

Drug(s) Targeting Cannabinoid receptor 1 (CB1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[20]
NABILONE	DMVRYT2	Insomnia	7A00-7A0Z	Approved	[21]
Orlistat	DMRJSP8	Obesity	5B81	Approved	[22]
SR141716A	DMCO5JZ	Obesity	5B81	Approved	[23]
Tebipenem	DMVSX6O	Urinary tract infection	GC08	Phase 3	[24]
Conatumumab	DM2UOSN	Colorectal cancer	2B91.Z	Phase 2	[25]
GW-42004	DMY3KSU	Lipid metabolism disorder	5C52.Z	Phase 2	[26]
SR-147778	DMNAECP	Obesity	5B81	Phase 2	[27]
Nimacimab	DM21Z68	Diabetic nephropathy	GB61.Z	Phase 2	[28]
AEF0117	DMQ1GH4	Marijuana use disorder	6C41	Phase 2	[29]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Acetylcholinesterase (AChE)	TT1RS9F	ACES_HUMAN	Inhibitor	[1]
Cannabinoid receptor 1 (CB1)	TT6OEDT	CNR1_HUMAN	Inhibitor	[1]
Fatty acid amide hydrolase (FAAH)	TTDP1UC	NOUNIPROTAC	Inhibitor	[1]

References

• [1] Activation of the endocannabinoid system by organophosphorus nerve agents. Nat Chem Biol. 2008 Jun;4(6):373-8.
• [2] Glutamate- and GABA-based CNS therapeutics. Curr Opin Pharmacol. 2006 Feb;6(1):7-17.
• [3] The general anesthetic propofol increases brain N-arachidonylethanolamine (anandamide) content and inhibits fatty acid amide hydrolase. Br J Pharmacol. 2003 Jul;139(5):1005-13.
• [4] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [5] Pharma & Vaccines. Product Development Pipeline. April 29 2009.
• [6] The Discovery and Development of Inhibitors of Fatty Acid Amide Hydrolase (FAAH). Bioorg Med Chem Lett. 2011 August 15; 21(16): 4674-4685.
• [7] Discovery of PF-04457845: A Highly Potent, Orally Bioavailable, and Selective Urea FAAH Inhibitor. ACS Med Chem Lett. 2011 Feb 10;2(2):91-96.
• [8] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1400).
• [9] A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351.
• [10] Evidence that the clinical effects of cholinesterase inhibitors are related to potency and targeting of action. Int J Clin Pract Suppl. 2002 Jun;(127):6-19.
• [11] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2465).
• [12] Acetylcholinesterase activity in Corbicula fluminea Mull., as a biomarker of organophosphate pesticide pollution in Pinacanauan River, Philippines. Environ Monit Assess. 2010 Jun;165(1-4):331-40.
• [13] [From symptomatic to disease modifying therapy Recent developments in the pharmacotherapy of Alzheimer's disease]. Fortschr Neurol Psychiatr. 2009 Jun;77(6):326-33.
• [14] Huperzine A attenuates cognitive deficits and brain injury in neonatal rats after hypoxia-ischemia. Brain Res. 2002 Sep 13;949(1-2):162-70.
• [15] Screening of acetylcholinesterase inhibitors by CE after enzymatic reaction at capillary inlet. J Sep Sci. 2009 May;32(10):1748-56.
• [16] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [17] Alpha6-containing nicotinic acetylcholine receptors dominate the nicotine control of dopamine neurotransmission in nucleus accumbens. Neuropsychopharmacology. 2008 Aug;33(9):2158-66.
• [18] The effects of topical ocular application of 0.25% demecarium bromide on serum acetylcholinesterase levels in normal dogs. Vet Ophthalmol. 2003 Mar;6(1):23-5.
• [19] Rational design of alkylene-linked bis-pyridiniumaldoximes as improved acetylcholinesterase reactivators. Chem Biol. 2003 Jun;10(6):491-502.
• [20] Emerging strategies for exploiting cannabinoid receptor agonists as medicines. Br J Pharmacol. 2009 Feb;156(3):397-411.
• [21] Novel 1',1'-chain substituted hexahydrocannabinols: 9-hydroxy-3-(1-hexyl-cyclobut-1-yl)-hexahydrocannabinol (AM2389) a highly potent cannabinoid r... J Med Chem. 2010 Oct 14;53(19):6996-7010.
• [22] Tetrahydrolipstatin analogues as modulators of endocannabinoid 2-arachidonoylglycerol metabolism. J Med Chem. 2008 Nov 13;51(21):6970-9.
• [23] Anti-obesity drugs. Expert Opin Pharmacother. 2008 Jun;9(8):1339-50.
• [24] Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60.
• [25] Clinical pipeline report, company report or official report of AstraZeneca (2009).
• [26] Company report (Gwpharm)
• [27] Surinabant, a selective cannabinoid receptor type 1 antagonist, inhibits 9-tetrahydrocannabinol-induced central nervous system and heart rate effects in humans.Br J Clin Pharmacol.2013 Jul;76(1):65-77.
• [28] Clinical pipeline report, company report or official report of Bird Rock Bio.
• [29] Clinical pipeline report, company report or official report of Affimed Therapeutics.